common.study.topics.clinical

Targeting Heavy Alcohol Use with Naltrexone

common.study.values.description

“Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM”

This is a double-blind, placebo-controlled trial of 120 binge-drinking MSM to 12 weeks of naltrexone 50mg, to be taken in anticipation of heavy drinking. Ethnically and racially diverse participants will be recruited using Respondent Driven Sampling as well as active field recruitment. MSM will be seen weekly for alcohol-metabolite urine testing, study drug dispensing, and brief counseling for alcohol use. Safety assessments and behavioral surveys will be completed monthly.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Placebo

Drug - Naltrexone

participant.views.study.view.additional

participant.views.study.view.scientific-title

Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM

common.study.values.clinical-trial-id

NCT02330419

participant.views.study.view.id

6dB82a